These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 8105671)

  • 21. Lipoprotein(a) is an independent risk factor for cardiovascular disease in heterozygous familial hypercholesterolemia.
    Holmes DT; Schick BA; Humphries KH; Frohlich J
    Clin Chem; 2005 Nov; 51(11):2067-73. PubMed ID: 16141286
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low-density lipoprotein apheresis as long-term treatment for children with homozygous familial hypercholesterolemia.
    Zwiener RJ; Uauy R; Petruska ML; Huet BA
    J Pediatr; 1995 May; 126(5 Pt 1):728-35. PubMed ID: 7751996
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of LDL apheresis in a case of homozygous familial hypercholesterolemia.
    Naveen T; Biswas A; Wig N; Soneja M; Jorwal P; Durga CS; Singla P; Chaudhary C; Baitha U
    Drug Discov Ther; 2019; 13(1):59-61. PubMed ID: 30880324
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Severe xanthomatosis in heterozygous familial hypercholesterolemia.
    Aljenedil S; Ruel I; Watters K; Genest J
    J Clin Lipidol; 2018; 12(4):872-877. PubMed ID: 29778561
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Familial hypercholesterolemia in children and adolescents: A clinical perspective.
    de Ferranti SD
    J Clin Lipidol; 2015; 9(5 Suppl):S11-9. PubMed ID: 26343208
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Two novel mutations in exon 3 and 4 of low density lipoprotein (LDL) receptor gene in patients with heterozygous familial hypercholesterolemia.
    Khan SP; Ghani R; Ahmed KZ; Yaqoob Z
    J Coll Physicians Surg Pak; 2011 Jul; 21(7):403-6. PubMed ID: 21777527
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.
    Robinson JG
    J Manag Care Pharm; 2013 Mar; 19(2):139-49. PubMed ID: 23461430
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term effect of low-density lipoprotein apheresis on plasma lipoproteins and coronary heart disease in native vessels and coronary bypass in severe heterozygous familial hypercholesterolemia.
    Richter WO; Donner MG; Höfling B; Schwandt P
    Metabolism; 1998 Jul; 47(7):863-8. PubMed ID: 9667236
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnosis and case finding in familial hypercholesterolemia.
    Pearson TA
    Am J Cardiol; 1993 Sep; 72(10):15D-17D. PubMed ID: 8213491
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia.
    Stein EA; Strutt K; Southworth H; Diggle PJ; Miller E;
    Am J Cardiol; 2003 Dec; 92(11):1287-93. PubMed ID: 14636905
    [TBL] [Abstract][Full Text] [Related]  

  • 31. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
    Jellinger PS; Handelsman Y; Rosenblit PD; Bloomgarden ZT; Fonseca VA; Garber AJ; Grunberger G; Guerin CK; Bell DSH; Mechanick JI; Pessah-Pollack R; Wyne K; Smith D; Brinton EA; Fazio S; Davidson M
    Endocr Pract; 2017 Apr; 23(Suppl 2):1-87. PubMed ID: 28437620
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk assessment and strategies to achieve lipid goals: lessons from real-world clinical practice.
    Schuster H
    Am J Med; 2004 Mar; 116 Suppl 6A():26S-30S. PubMed ID: 15050189
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stress testing response in women heterozygous for familial hypercholesterolemia.
    Kolovou GD; Damaskos DS; Anagnostopoulou KK; Salpea KD; Dritsas A; Giannakopoulou V; Vasiliadis IK; Cokkinos DV
    Int J Cardiol; 2007 Oct; 122(1):96-7. PubMed ID: 17239976
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recommendations for the management of patients with familial hypercholesterolemia.
    Feldman DI; Blaha MJ; Santos RD; Jones SR; Blumenthal RS; Toth PP; Sperling LS; Martin SS
    Curr Atheroscler Rep; 2015 Jan; 17(1):473. PubMed ID: 25404096
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lipoprotein-apheresis in familial hypercholesterolemia: Long-term patient compliance in a French cohort.
    Beliard S; Gallo A; Duchêne E; Carrié A; Bittar R; Chapman MJ; Bruckert E; Saheb S
    Atherosclerosis; 2018 Oct; 277():66-71. PubMed ID: 30176566
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of people with heterozygous familial hypercholesterolemia.
    Haase A; Goldberg AC
    Curr Opin Lipidol; 2012 Aug; 23(4):282-9. PubMed ID: 22801386
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study.
    Kolovou V; Katsiki N; Makrygiannis S; Mavrogieni S; Karampetsou N; Manolis A; Melidonis A; Mikhailidis DP; Kolovou GD
    J Cardiovasc Pharmacol Ther; 2021 Jan; 26(1):51-58. PubMed ID: 32729335
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypolipidemic treatment of heterozygous familial hypercholesterolemia: a lifelong challenge.
    Vuorio AF; Kovanen PT; Gylling H
    Expert Rev Cardiovasc Ther; 2004 May; 2(3):405-15. PubMed ID: 15151486
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry.
    deGoma EM; Ahmad ZS; O'Brien EC; Kindt I; Shrader P; Newman CB; Pokharel Y; Baum SJ; Hemphill LC; Hudgins LC; Ahmed CD; Gidding SS; Duffy D; Neal W; Wilemon K; Roe MT; Rader DJ; Ballantyne CM; Linton MF; Duell PB; Shapiro MD; Moriarty PM; Knowles JW
    Circ Cardiovasc Genet; 2016 Jun; 9(3):240-9. PubMed ID: 27013694
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Subclinical coronary atherosclerosis and cardiovascular risk stratification in heterozygous familial hypercholesterolemia patients undergoing statin treatment.
    Miname MH; Bittencourt MS; Nasir K; Santos RD
    Curr Opin Lipidol; 2019 Apr; 30(2):82-87. PubMed ID: 30649025
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.